Zone of inhibition (mm)/MIC (μg/ml)    
Entry+ S. typhi V. cholerae S. dysenteriae E. faecalis S. aureus C. albicans
4a 8/100 8/10 7/100 8/100 9/100 7/100
4b 4/100 5/100 2/100 ND 6/100 6/100
4c 5/1000 4/100 3/100 5/100 4/100 ND
4d 4/100 5/100 4/100 3/1000 4/100 2/100
4e 5/100 6/100 5/100 5/100 6/1000 4/100
4f 7/100 8/1000 7/100 8/100 7/1000 6/1000
4g 5/1000 5/100 6/100 7/1000 8/100 7/100
4h 14/1 13/10 12/10 12/10 13/10 10/100
4i 6/10 7/100 7/1000 7/100 6/100 5/100
6a 5/100 5/100 6/1000 5/1000 7/100 5/100
6b 4/100 5/100 5/100 4/10 5/100 4/100
6c 5/1000 4/1000 6/100 5/1000 4/1000 5/100
6d 5/1000 4/1000 6/100 7/100 5/1000 4/1000
6e 4/1000 5/1000 5/1000 4/1000 5/100 4/1000
6f 3/1000 4/1000 3/100 3/100 4/100 2/1000
6g 2/1000 2/100 3/100 3/1000 4/1000 2/>1000
6h 2/1000 2/1000 4/10 3/100 4/1000 2/1000
6i 3/1000 4/100 3/1000 2/100 4/1000 ND
6j 4/1000 3/1000 5/100 ND 4/1000 ND
Standard* 12/10 12/1 13/10 12/10 11/10 11/10
*Ciprofloxacin for bacteria and Griseofulvin for dermatophytic fungi; + 50 µg compound   per well; ND: Not Determined
Table 3: Antimicrobial activities of newly synthesized putrescine bisamide derivatives against various human pathogens.